DE69527145T2 - Verfahren zur behandlung von blutungsstorungen - Google Patents

Verfahren zur behandlung von blutungsstorungen

Info

Publication number
DE69527145T2
DE69527145T2 DE69527145T DE69527145T DE69527145T2 DE 69527145 T2 DE69527145 T2 DE 69527145T2 DE 69527145 T DE69527145 T DE 69527145T DE 69527145 T DE69527145 T DE 69527145T DE 69527145 T2 DE69527145 T2 DE 69527145T2
Authority
DE
Germany
Prior art keywords
treating
vwd
bleeding disorders
von willebrand
congenital
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527145T
Other languages
English (en)
Other versions
DE69527145D1 (de
Inventor
A Kaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE69527145D1 publication Critical patent/DE69527145D1/de
Publication of DE69527145T2 publication Critical patent/DE69527145T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69527145T 1994-07-22 1995-04-27 Verfahren zur behandlung von blutungsstorungen Expired - Fee Related DE69527145T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/278,765 US5582821A (en) 1994-07-22 1994-07-22 Methods for treating bleeding disorders
PCT/US1995/005439 WO1996003143A1 (en) 1994-07-22 1995-04-27 Methods for treating bleeding disorders

Publications (2)

Publication Number Publication Date
DE69527145D1 DE69527145D1 (de) 2002-07-25
DE69527145T2 true DE69527145T2 (de) 2003-02-13

Family

ID=23066267

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527145T Expired - Fee Related DE69527145T2 (de) 1994-07-22 1995-04-27 Verfahren zur behandlung von blutungsstorungen

Country Status (10)

Country Link
US (1) US5582821A (de)
EP (1) EP0772450B1 (de)
JP (1) JPH10503195A (de)
AT (1) ATE219372T1 (de)
AU (1) AU2381795A (de)
DE (1) DE69527145T2 (de)
DK (1) DK0772450T3 (de)
ES (1) ES2177646T3 (de)
PT (1) PT772450E (de)
WO (1) WO1996003143A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO439396A0 (en) 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
EP1368486A4 (de) * 1999-07-15 2009-04-01 Genetics Inst Llc Formulierungen für il-11
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
CA2835434A1 (en) 2011-05-17 2012-11-22 Velico Medical, Inc. Improved platelet storage using a sialidase inhibitor
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
CA2887083A1 (en) 2012-10-05 2014-04-10 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
US20150160214A1 (en) * 2013-12-05 2015-06-11 Mayo Foundation For Medical Education And Research Quantitation of Cellular Adhesion Dynamics Across Immobilized Receptors Under Rheological Shear Flow
EP4298124A1 (de) 2021-02-26 2024-01-03 Bayer Aktiengesellschaft Inhibitoren von il-11 oder il-11ra zur verwendung bei der behandlung abnormaler uterusblutungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
ATE167896T1 (de) * 1990-08-29 1998-07-15 Genetics Inst Aus mehreren domänen bestehende hämatopoese- stimulatoren
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0560998A4 (en) * 1991-10-09 1993-12-01 Toray Industries, Inc. Medicine for preventing and treating bleeding tendency

Also Published As

Publication number Publication date
PT772450E (pt) 2002-10-31
EP0772450A1 (de) 1997-05-14
WO1996003143A1 (en) 1996-02-08
EP0772450B1 (de) 2002-06-19
ES2177646T3 (es) 2002-12-16
JPH10503195A (ja) 1998-03-24
AU2381795A (en) 1996-02-22
DE69527145D1 (de) 2002-07-25
DK0772450T3 (da) 2003-04-14
US5582821A (en) 1996-12-10
ATE219372T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
ATE66374T1 (de) Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69428905T2 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
DE69521623D1 (de) Zusammensetzung für die stabilisation von zahnprothesen
DE69333286D1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
DE69527145T2 (de) Verfahren zur behandlung von blutungsstorungen
DE69214610D1 (de) Verfahren zur Behandlung von Erdgas
DE69129115D1 (de) Neues verfahren zur behandlung von depression
ATE210455T1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE25690T1 (de) Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems.
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
DE60042171D1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
DE3865484D1 (de) Verfahren zur herstellung von urantetrafluorid und von schwefelfluoriden mittels redoktion von uranhexafluorid.
Vignesh et al. Management of Haemorrhage in Oral Surgery
DE60041266D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69331193D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen, die durch endothelzellen und fibrinogen ausgelöst werden
DK563886A (da) Terapeutisk komposition
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
AT377983B (de) Verfahren zur herstellung von reiner cyanursaeure

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee